For early-stage companies spinning out of Newcastle, Durham, Edinburgh or Glasgow, conference strategy isn’t a nice-to-have.

It’s where investors, partners and customers decide whether you’re worth their time.

The challenge

You’ve spun out of the lab.

The IP is protected, the founding team is assembled, and the first funding round is either done or in progress.

Now comes a question that trips up most early-stage life sciences companies: which conferences are actually worth attending? 

In the North East of England and Scotland, a genuinely world-class cluster of biotech, medtech and medical device innovation has emerged, from the universities of Newcastle, Durham, Edinburgh, St Andrews and Aberdeen through to the growing commercial hubs in the Tyne and Wear corridor and the Edinburgh BioQuarter.

The challenge isn’t a lack of opportunity. It’s avoiding the trap of spreading yourself too thin before you’ve established a clear market position.

Define your objective before you book anything

For a spin-out company, no two conferences serve the same purpose. Some are explicitly designed for investor introductions, MedCity Connects, BioTrinity, and the Scottish EDGE finals all attract early-stage capital.

Others, like Arab Health or Medtech Summit, are where your potential NHS or private sector customers are sitting.

There is a third category: events like the Northeast England Life Sciences Conference or Converge, the Scottish commercialisation challenge, that build regional profile and connect you with the ecosystem you actually live and work in.

The mistake most spin-outs make is treating every conference as everything at once.

A 12-person company cannot realistically generate investor leads, close distribution partnerships, and build brand awareness at the same event.

Pick one primary objective per event and design your presence around it.

Start-up reality check – For a pre-Series A medtech company, the honest answer is usually: two or three conferences per year, chosen deliberately, executed well. Not eight events with an overworked founder trying to be everywhere at once.

Who is actually in the room?

Attendance figures are the vanity metric of conference selection. An event with 4,000 attendees means nothing if fewer than 50 of them are relevant to your specific niche whether that’s surgical robotics, point-of-care diagnostics, digital health platforms or drug delivery innovation.

Before you commit budget, look past the headline numbers.

• Request the delegate breakdown from the organiser.
• Check LinkedIn for past attendees.
• If the event has a published speaker list, look at who is on it and what their actual seniority and buying authority looks like.

“Smaller, more targeted events almost always create better conversations for early-stage companies than enormous trade shows where you’re competing for attention against 400 exhibitors.”

For North East and Scottish spin-outs specifically, there’s also strong value in the regional ecosystem events.

BioNow, NovaBiotics, and the Medicines Discovery Catapult network, alongside events hosted by the Edinburgh BioQuarter and the North East BIC, tend to draw exactly the collaborative partners, angel investors and NHS innovation leads that early-stage life sciences companies need to engage.

🏴󠁧󠁢󠁳󠁣󠁴󠁿 The Scottish life sciences advantage

Scotland has over 750 life sciences organisations employing 40,000+ people, with a particular concentration in diagnostics, medical devices and digital health.

Events like the Scottish Life Sciences Association annual conference give early-stage companies direct access to NHS Scotland innovation procurement, SNIB funding streams, and the University of Edinburgh and Glasgow commercialisation pipelines.

🌊 North East England: more than a cluster

With Newcastle University’s Institute of Cellular Medicine, Durham University’s Biophysical Sciences Institute, and the NIHR Newcastle Clinical Research Facility all spinning out commercial ventures, the Tyne and Wear corridor has become a genuine biotech destination.

The Evolent Health accelerator and Northstar Ventures actively back early-stage life sciences spin-outs from the region.

Should you exhibit, or just attend?

This is one of the most consequential decisions a start-up makes, and the default answer for most early-stage companies should be: attend first, exhibit later.

Exhibition stands carry significant cost – floor space, shell scheme or custom build, graphics, logistics, staffing, that can quickly consume a meaningful portion of a seed-stage marketing budget. Before committing, ask whether the same outcome could be achieved through a delegate badge, a curated meeting schedule, and a well-placed poster presentation or speaking slot.

• Does the event offer investor meeting programmes? (Many do use them before you build a stand.)
• Is there a start-up showcase, pitch competition or innovation zone you could enter at lower cost?
• Are the key people you need to meet likely to walk the floor, or do they stay in the conference sessions?
• Do you have the team capacity to staff a stand properly, or will it look underserved?
• Can a smaller presence – a pull-up banner and a meeting table achieve what a full exhibition stand would?

When you do exhibit, size and spend are far less important than the clarity of your message and the quality of the team you put on the stand.

A well-briefed two-person team with a clear story will outperform a lavish build staffed by people who aren’t confident in their narrative every time.

The story a spin-out has to tell

Academic credibility is your most powerful asset as a spin-out and your biggest communication risk. Conferences are not lecture halls.

The language that works beautifully in a journal article or a grant application frequently fails in a three-minute conversation at an exhibition stand or over coffee between sessions.

Your conference narrative needs to answer four questions almost instantly:

• What problem does this solve?
• Who has this problem?
• How does your solution work at a high level?
• Also (and critically for investors) why are you the team to build this?

Common mistake – Leading with the technology rather than the unmet need. Investors and commercial partners want to understand the market problem first. The elegance of your platform technology is compelling context, not the opening line.

Proof points matter enormously for early-stage companies in medtech and biotech. Clinical validation data, even from small feasibility studies, is powerful. Letters of support from NHS trusts, early commercial agreements or pilot partnerships, and named academic collaborators with recognisable institution affiliations all build credibility rapidly.

Don’t bury these in slide decks. Make them visible and referenceable in conversation.

---

Plan for the follow-up before you arrive

For most companies, the real commercial value of a conference is unlocked in the three weeks after it ends, not while you’re standing on the show floor.

Yet most early-stage companies treat follow-up as an afterthought, returning to a pile of business cards and no system for progressing any of them.

Before you attend, agree on what a meaningful outcome looks like.

That might be five investor meetings booked within two weeks, three qualified conversations with NHS procurement leads, or two new partnership introductions.

Write it down, build a simple CRM entry or even a spreadsheet template that your team completes on the day for every meaningful conversation.

The best conference strategy for a growing biotech or medtech start-up is ultimately about compounding relationships over time.

The investor you meet at a Scottish life sciences event this year may lead your Series A round eighteen months from now.

Treat every meaningful conversation as the beginning of something long-term, not a transaction to be closed immediately.

“The conference isn’t the event. The follow-up is the event. Everything that happens on the show floor is just the introduction.”

Be selective. Be intentional. Build a strategy.

The life sciences conference calendar in the UK is genuinely extensive and the temptation to show up everywhere is understandable.

Conference presence feels like momentum.

However, for an early-stage spin-out operating with finite resources and a founding team already stretched across R&D, regulatory, and commercial workstreams, scattered conference activity is one of the most common ways that marketing budget gets wasted.

The most effective approach is to choose two or three events where your audience will genuinely be present, invest properly in your presence and preparation for those events, and execute the follow-up with the same rigour you’d bring to any other commercial activity. Done well, this approach consistently outperforms companies that attend everything with no clear strategy.

For spin-outs from Newcastle, Durham, Edinburgh, St Andrews and the wider North East and Scottish cluster, there is a genuinely differentiated story to tell about world-class university research translated into commercial applications, in a region with supportive innovation infrastructure, NHS access, and a growing community of sector-specific investors.

That story deserves to be told well, in the right rooms, to the right people.